Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.298 EUR | -12.87% |
|
-.--% | -.--% |
05-31 | Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-15 | Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M | MT |
Sales 2022 | 25.74M 27.52M 37.68M | Sales 2023 | 32.25M 34.48M 47.21M | Capitalization | 25.59M 27.35M 37.46M |
---|---|---|---|---|---|
Net income 2022 | -44M -47.04M -64.42M | Net income 2023 | - 0 0 | EV / Sales 2022 | 3.59 x |
Net cash position 2022 | 4.88M 5.21M 7.14M | Net cash position 2023 | 1.93M 2.07M 2.83M | EV / Sales 2023 | 0.73 x |
P/E ratio 2022 |
-1.98
x | P/E ratio 2023 |
-40.1
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.83% |
Latest transcript on Biofrontera
1 day | -12.87% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 55 | 22-09-11 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 21-12-13 | |
Heikki Lanckriet
BRD | Director/Board Member | 46 | 21-12-13 |
Helge Lubenow
CHM | Chairman | 56 | 21-12-13 |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- B8FK Stock
- B8F Stock